 occurred in the per protocol
symptomatic patients in ROADSTER-2 for a combined
30-day stroke and death rate of 0.6%.44,45 A more recent
study examined 3286 propensity-matched patients from
the VQI and demonstrated a signiÔ¨Åcantly lower incidence of in-hospital stroke and death for the patients
treated with TCAR vs TF-CAS (1.6% vs 3.1%; RR